Satellos Bioscience Receives US Patent for Forazapadin

MT newswire2026/10/05 11:58

07:58 AM EDT, 10/05/2026 (MT Newswires) -- Satellos Bioscience (MSLE) said Monday that it received a US patent covering the composition of matter claims for its lead clinical-stage drug candidate forazapadin to restore muscle regeneration and repair in patients with degenerative muscle diseases. The company said the patent covers a broader class of AAK1 inhibitors and related compounds under its muscle regeneration platform. Satellos said the patent provides intellectual property protection through Sept. 6, 2044. The company may also qualify for a patent term extension for forazapadin if the drug receives US marketing approval, according to Satellos. Satellos said it plans to seek inclusion of the patent in the FDA's Orange Book following potential US approval of forazapadin.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51